Literature DB >> 12121507

Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.

Hiroaki Okuda1, Toshimi Nakanishi, Kazuko Takatsu, Akiko Saito, Naoaki Hayashi, Masakazu Yamamoto, Ken Takasaki, Masayuki Nakano.   

Abstract

BACKGROUND: There has been no study of the clinicopathologic features of patients with hepatocellular carcinoma (HCC) who are seropositive for lectin-reactive alpha-fetoprotein (AFP-L3) alone, or seropositive for AFP-L3 and seronegative for des-gamma-carboxy prothrombin (DCP) in comparison with those who are seropositive for DCP alone. Thus, the present comparative study was performed.
METHODS: The clinicopathologic features of HCC patients with either one or two tumors who underwent a hepatectomy (n = 88) were compared among the following five groups according to the seropositivity of AFP, AFP-L3 and DCP: (i) group A, seropositive for AFP above 100 ng/mL, AFP-L3 above 15% and DCP above 100 mAU/mL; (ii) group B, seropositive for AFP-L3 and seronegative for DCP below 40 mAU/mL; (iii) group C, seronegative for AFP below 20 ng/mL, AFP-L3 below 15% and seropositive for DCP; (iv) group D, seropositive for AFP and seronegative for AFP-L3 and DCP; and (v) group E, seronegative for AFP, AFP-L3 and DCP.
RESULTS: Group B patients showed a higher incidence of infiltrative-type HCC with an irregular margin (P < 0.05) and a higher frequency of poorly differentiated HCC (P < 0.01) compared with group C patients. Group A patients had larger tumors and more massive-type tumors than group B patients. Our HCC cases showed that advanced clinicopathologic features were demonstrated in the order of group B, group C and group D. Group A and B patients and group D and E patients showed similar characteristics.
CONCLUSIONS: Hepatocellular carcinoma patients who were seropositive for AFP-L3 and seronegative for DCP demonstrated clinicopathologic features of more advanced HCC compared with those who were seropositive for DCP alone. Copyright 2002 Blackwell Publishing Asia Pty Ltd

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12121507     DOI: 10.1046/j.1440-1746.2002.02806.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  17 in total

Review 1.  Infiltrating hepatocellular carcinoma: seeing the tree through the forest.

Authors:  Aram Demirjian; Peter Peng; Jean-Francois H Geschwind; David Cosgrove; Jacob Schutz; Ihab R Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2011-07-02       Impact factor: 3.452

2.  AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC.

Authors:  Kentaroh Yamamoto; Hiroshi Imamura; Yutaka Matsuyama; Yukio Kume; Hitoshi Ikeda; Gary L Norman; Zakera Shums; Taku Aoki; Kiyoshi Hasegawa; Yoshifumi Beck; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  J Gastroenterol       Date:  2010-07-13       Impact factor: 7.527

3.  Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.

Authors:  Atsushi Nanashima; Naota Taura; Takafumi Abo; Tatsuki Ichikawa; Ichiro Sakamoto; Takeshi Nagayasu; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2011-06-25       Impact factor: 3.199

4.  Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma.

Authors:  Yoshiyuki Mori; Hideyuki Tamai; Naoki Shingaki; Kosaku Moribata; Tatsuya Shiraki; Hisanobu Deguchi; Kazuki Ueda; Shotaro Enomoto; Hiroto Magari; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Kimihiko Yanaoka; Masashi Oka; Masao Ichinose
Journal:  Hepatol Int       Date:  2009-04-29       Impact factor: 6.047

5.  Modified Japan Integrated Staging is currently the best available staging system for hepatocellular carcinoma patients who have undergone hepatectomy.

Authors:  Atsushi Nanashima; Yorihisa Sumida; Takafumi Abo; Hisakazu Shindou; Hidetoshi Fukuoka; Hiroaki Takeshita; Shigekazu Hidaka; Kenji Tanaka; Terumitsu Sawai; Toru Yasutake; Takeshi Nagayasu; Katsuhisa Omagari; Mariko Mine
Journal:  J Gastroenterol       Date:  2006-03       Impact factor: 7.527

Review 6.  Serum tumor markers for detection of hepatocellular carcinoma.

Authors:  Lin Zhou; Jia Liu; Feng Luo
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

7.  A novel biomarker TERTmRNA is applicable for early detection of hepatoma.

Authors:  Norimasa Miura; Yukio Osaki; Miki Nagashima; Michimori Kohno; Kensho Yorozu; Kohei Shomori; Takamasa Kanbe; Kenji Oyama; Yukihiro Kishimoto; Shigeo Maruyama; Eijiro Noma; Yutaka Horie; Masatoshi Kudo; Seigo Sakaguchi; Yasuaki Hirooka; Hisao Ito; Hironaka Kawasaki; Junichi Hasegawa; Goshi Shiota
Journal:  BMC Gastroenterol       Date:  2010-05-18       Impact factor: 3.067

8.  Hypervascular hepatocellular carcinomas showing hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: a possible subtype with mature hepatocyte nature.

Authors:  Norihide Yoneda; Osamu Matsui; Azusa Kitao; Ryuichi Kita; Kazuto Kozaka; Wataru Koda; Satoshi Kobayashi; Toshifumi Gabata; Hiroko Ikeda; Yasuni Nakanuma
Journal:  Jpn J Radiol       Date:  2013-06-16       Impact factor: 2.374

Review 9.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

10.  Postoperative changes in protein-induced vitamin K absence or antagonist II levels after hepatectomy in patients with hepatocellular carcinoma: relationship to prognosis.

Authors:  A Nanashima; Y Sumida; S Tobinaga; K Shibata; H Shindo; M Obatake; S Shibasaki; N Ide; Takeshi Nagayasu
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.